Antibody therapy - activities

Covid: Xevudy, the promising antibody therapy approved by the Haute Autorité de Santé

This Friday January 7, 2022, the Haute Autorité de Santé announced they have approved the use of Xevudy against Covid, a promising synthesized antibody therapy. The drug seems particularly effective against the Omicron variant. Here is more on the matter!

Covid: Xenothera's therapy, Xav-19, working against Omicron

And what if, amid the fight against Covid, one could rely – in addition to the upcoming vaccine – on antibody-based treatments? After Bamlanivimab – the treatment developed by the Eli Lilly laboratory – or even Regeneron, this is now French Nantes-based laboratory Xenothera’s turn to present a treatment undergoing clinical trials, Xav-19. According to primary studies, the therapy is effective against Covid's Omicron variant, but waiting for the green light for marketing from early 2022.

Coronavirus: an AstraZeneca antibody therapy approved by the Haute Autorité de Santé

This Friday December 10, the Haute Autorité de Santé announced they have approved the use of Evusheld (tixagevimab-cilgavimab), a coronavirus monoclonal antibody-based therapy developed by AstraZeneca. But the therapy includes cardiovascular risks… Here is more on the matter.

Covid – AstraZeneca: conclusive results for their antibody therapy under rolling review

This Thursday November 18, 2021, AstraZeneca laboratory revealed successful clinical trials for their antibody-based Covid therapy. This therapy is said to cut risks of developing severe disease by 67%. Here is more on the matter!

Covid: a new antibody therapy developed by Spiklmm under rolling review

Is a new Covid therapy based on monoclonal antibodies soon to be reviewed? This is what infectious disease specialist and member of Spiklmm biotech administration board Karine Lacombe has explained. The very laboratory is developing this therapy. Clinical trials are expected to start from the beginning of 2022.

Covid: Ronapreve, the preventive antibody therapy for immunocompromised people approved by the HAS

Less protected against coronavirus, immunocompromised people will be allowed to get a preventive Covid-19 therapy based on monoclonal antibodies, the Haute Autorité de Santé stated.

Covid: why is looking for a therapy more difficult than for a vaccine?

As several Covid vaccines are being given in the whole world, over 1.5 year of pandemic, the search for therapies is still groping around. Why is looking for a coronavirus therapy more difficult? Food for thoughts…

Covid: WHO to review three new therapies

Are new Covid therapies to be reviewed soon? This is what the World Health Organization or WHO announced this Wednesday August 11, 2021, stating WHO’s Solidarity clinical trial enters a new phase with three new candidate drugs namely artesunate, imatinib and infliximab.

Coronavirus: The European Union ordered a new antibody therapy

This Wednesday July 28, the European Union announced they have secured a deal for a new experimental coronavirus therapy, Sotrovimab, developed by UK laboratory GSK. A promising monoclonal antibody therapy.

Covid: effectiveness of monoclonal antibodies challenged by variants

As Covid variants keep on spreading across the world, Eli Lilly laboratories has seen their approval removed for marketing bamlanivimab, as a monotherapy, being a therapy based on monoclonal antibodies. Why? Its effectiveness challenged by new coronavirus strains. Keep reading to find out more!

Covid: Eli Lilly antibody therapy said to reduce hospitalization risks, a study finds

As the race for Covid vaccines and therapies is speeding up all over the world, drugmaker Eli Lilly announced this Wednesday March 10 their antibody therapy mixing Bamlanivimab and Etsesevimab is said to reduced by 87% hospitalization and death risk in the event of severe infection. A combined therapy that received emergency use authorization back to late February from the Food & Drug Administration.